Good company but lousy stock.
Unfortunately I hold a few of these.
Short term and from by craptastic buy point I would agree. But YTD the stock has done fairly well.
In any case I pulled my lowball offers since this thing looks like it might blow thru lower teens at this point.
Hope I'm wrong.
More great sounding numbers, but the market is saying this thing should only be valued at less than $200 million.
Why does every other biotec sell at multiple future sales but this one?
I know I suck at biotec investing (maybe investing in general) but every time I think I have these figured out I'm wrong.
Not sure since it's an Israeli company that it should support a lower market cap ...check out TEVA.
Anyhow, I think the low float is working against us. I usually invest in low floaters and they seem to be easily manipulated by algos and bots.
The last big low floater I hit was a 3D printing company out of Sweden AMAVF. It took a while but that one finally worked out. I bought at 36 and it ran to 200 before they split it.
I see similar value here.
But this time I'll set up a bunch of smaller lowball offers hoping they get hit instead of stupidly chasing it like I did on Monday.
Roth Capital has a target of $30.
Nothing makes sense here.
Greatday you might be onto something here since it doesn't seem quite right to me.
Instead I wish they could partner and get an upfront payment for RHB-104 or add debt since that drug is so close anyway, that way they wouldn't have to dilute.
Btw did you used to post in the VTSS board long time ago?
And this Chrons drug is entering phase III?
I've seen lesser drugs in earlier development valued at many multiple levels than RDHL.
Almost seems the market price is being manipulated for maybe a takeover??
In order to keep you shares from getting lent out to shorts.
I set one @ $350 a share.
$700 mil market cap for a constipation drug??
June 17, 2015
RedHill Biopharma Shares Could Reach $30
RedHill Biopharma (RDHL: Nasdaq)
By Roth Capital Partners ($16.46, June 15, 2015)
RedHill Biopharma announced positive top-line data Monday morning for RHB-105 to treat Helicobacter pylori.
The eradication rate for RHB-105 of 89.4% easily topped historical controls of 70% (p
Thx for the projection I need all the pep talk I can get after today!
I thought RDHL had several other drugs in active development.
Or are you implying no other drugs in development for H pylori?
Thx for the update!